Pixium Vision announces the launch of a process to find buyers
Paris, France, October 18, 2023
– 7:30 p.m. (CET) – Pixium Vision SA (Euronext Growth Paris – FR001400JX97; Mnemo: ALPIX) (the “
Company
), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independently, announces that a call for tenders for the resumption of the Company’s activity will be published tomorrow.
Indeed, having been unable to find financial investors within the constrained timetable and commensurate with the Company’s needs, a backup plan is not possible. Consequently, the Company will request the conversion of the safeguard procedure into judicial recovery.
It is in this context that the judicial administrators intend to set the deadline for submitting takeover offers at November 20, 2023 at 12:00 p.m.
Interested candidates are invited to contact the Judicial Administrators, SCP Abitbol & Rousselet, represented by Joanna Rousselet, and Selarl FHB, represented by Hélène Bourbouloux.
Access to an electronic data room will be authorized after signing a confidentiality agreement and a brief presentation of the candidate.
Information will be regularly communicated to the market on the progress of the procedure and, more generally, the financial situation of the Company.
About Pixium Vision
Pixium Vision
creates a world of bionic vision for people who have lost their sight, allowing them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with surgery and a rehabilitation period. Prima System miniature wireless subretinal photovoltaic implant is in clinical trials for patients who have lost vision due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the world’s most prestigious vision research institutions, such as Stanford University in California, the Vision Institute in Paris, Moorfields Eye Hospital in London, the Institute of Ocular Microsurgery (IMO) in Barcelona, University Hospital Bonn and UPMC in Pittsburgh, Pennsylvania. The company is EN ISO 13485 certified and is qualified as an “Innovative Company” by Bpifrance.
Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of the risks and uncertainties that could cause the actual results, financial condition, performance or achievements of the Company to differ from those contained in the forward-looking statements, please refer to the Risk Factors section of the Financial Report 2022 Annual Report of the Company and other documents filed by the Company with the AMF, which is available on the AMF website (www.amf-france.org) or on the Company’s website.
For more information
: http://www.pixium-vision.com/fr
Follow us on @PixiumVision; www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
|
Investor Relations Pixium Vision |
Media Relations Rose Piquante Consulting |
Attachment
PR – launch of call for tenders – 17.10.23 FR